Indeed. Discontinuance is a decision made by caregivers, and the problems which lead to that are so much less in infants; to be blunt, cleaning up after a bout of diarrhea in a baby is a lot less trouble than after one in a 35 year old woman. As genetic testing progresses, the ability to diagnose Retts at an early stage will be improved, and instead of seeing minor progress in adults, there will undoubtedly be major progress in infants where Daybue could have a much more significant benefit. It would be interesting to see some figures relating to younger children, but I suppose the population is too small at the moment.
Acadia, page-448
-
- There are more pages in this discussion • 431 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$14.05 |
Change
-0.510(3.50%) |
Mkt cap ! $1.795B | |||
| Open | High | Low | Value | Volume |
| $14.38 | $14.42 | $13.94 | $6.419M | 454.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 500 | $13.99 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $14.07 | 6644 | 4 |
View Market Depth
| Last trade - 16.10pm 04/10/2024 (20 minute delay) ? |
| NEU (ASX) Chart |